Treatments and Outcomes in Neuroendocrine Patients Treated with Long-Acting Somatostatin Analogues: An Italian Real-World Propensity Score-Matched Cohort Study

被引：0

作者：

Ranallo, Nicoletta ^{[1
]}

Roncadori, Andrea ^{[2
]}

Gentili, Nicola ^{[3
]}

Balzi, William ^{[2
]}

Altini, Mattia ^{[4
]}

Ghini, Virginia ^{[1
]}

Maltoni, Roberta ^{[2
]}

Andalo, Alice ^{[3
]}

Cavallucci, Martina ^{[3
]}

Sansovini, Maddalena ^{[5
]}

Fausti, Valentina ^{[1
]}

Montella, Maria Teresa ^{[2
]}

Massa, Ilaria ^{[2
]}

Danesi, Valentina ^{[2
]}

机构：

[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Clin & Expt Oncol Immunotherapy Rare Canc & Biol R, I-47014 Meldola, Italy

[2] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Healthcare Adm, Outcome Res, I-47014 Meldola, Italy

[3] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Healthcare Adm, Data Unit, I-47014 Meldola, Italy

[4] Assistenza Osped Reg Emilia Romagna, I-40127 Bologna, Italy

[5] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Nucl Med Unit, I-47014 Meldola, Italy

来源：

BIOMEDICINES | 2025年 / 13卷 / 02期

关键词：

neuroendocrine tumour (NET); real-world evidence; somatostatin analogue (SSA); lanreotide; octreotide; propensity score matching (PSM); Italy; TREATMENT PATTERNS; TUMORS; OCTREOTIDE; LANREOTIDE; EPIDEMIOLOGY; MANAGEMENT; DIAGNOSIS; SURVIVAL; DATABASE; CARE;

D O I：

10.3390/biomedicines13020515

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Objectives: The aim of this study was to investigate the treatment patterns and outcomes in two propensity score-matched cohorts of patients with neuroendocrine tumours (NETs) treated with first-line somatostatin analogue (SSA). Methods: Metastatic NET patients treated with first-line SSA (2009-2022) were retrospectively examined. First-line lanreotide vs. octreotide cohorts were matched 1:1 by propensity scores for demographics, tumour characteristics, and diagnosis year. Progression-free survival (PFS) and overall survival (OS) were analysed using Kaplan-Meier analysis and the Cox proportional hazards model. Results: Among 441 patients, 310 were matched (155 in both the octreotide and lanreotide groups). First-line SSA was monotherapy (63.5%) or combination with other medications (36.5%). A total of 77% of second-line patients (188/244) maintained their initial SSA medication in combination with other therapies. Radioligand therapy with lanreotide (N = 72; 29.5%) or octreotide (N = 70; 28.7%) was the most common second-line treatment. First-line lanreotide and octreotide cohorts had similar median PFS (15.5; 95% CI: 13.6-19.1 vs. 14.0; 95% CI: 12.0-15.8 months), despite octreotide having a 36% higher likelihood of moving to the second line than lanreotide (95% CI: 1.05-1.76, p = 0.018). Multiple metastases (HR = 1.45; p = 0.004, 95% CI: 1.13-1.87) and Ki-67 > 20% (HR = 2.34; p < 0.001, 95% CI: 1.43-3.83) were significantly associated with the worst PFS. First-line lanreotide patients had a median OS of 10.4 years (95% CI: 7.5-NA) and octreotide 9.2 years (95% CI: 7.3-NA) (p = 0.537). Bone metastases increased death risk by 91% (p = 0.014; 95% CI: 1.14-3.20). Conclusions: SSA monotherapy is the main first-line treatment and most subsequent treatments include SSA with additional medications. Cohorts had similar PFS/OS, but octreotide demonstrated a 36% significantly higher likelihood of moving to the second-line treatment.

引用

页数：14

共 38 条

[1] Kaltsas G.A., Besser G.M., Grossman A.B., The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors, Endocr. Rev, 25, pp. 458-511, (2004)
[2] Trama A., Mallone S., Ferretti S., Meduri F., Capocaccia R., Gatta G., Bellu F., Mazzoleni G., Dal Cappello T., Giacomin A., Et al., The Burden of Rare Cancers in Italy: The Surveillance of Rare Cancers in Italy (RITA) Project, Tumori, 98, pp. 550-580, (2012)
[3] Busco S., Buzzoni C., Mallone S., Trama A., Castaing M., Bella F., Amodio R., Bizzoco S., Cassetti T., Cirilli C., Et al., Italian cancer figures—Report 2015: The burden of rare cancers in Italy, Epidemiol. Prev, 40, pp. 1-120, (2016)
[4] Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.-N., Rashid A., Et al., One Hundred Years after “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States, J. Clin. Oncol, 26, pp. 3063-3072, (2008)
[5] Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., Shih T., Yao J.C., Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States, JAMA Oncol, 3, pp. 1335-1342, (2017)
[6] Das S., Dasari A., Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?, Curr. Oncol. Rep, 23, pp. 10-20, (2021)
[7] Fraenkel M., Kim M., Faggiano A., De Herder W.W., Valk G.D., Incidence of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review of the Literature, Endocr. Relat. Cancer, 21, pp. 153-163, (2014)
[8] Taal B.G., Visser O., Epidemiology of Neuroendocrine Tumours, Neuroendocrinology, 80, pp. 3-7, (2004)
[9] Fazio N., de Braud F., Delle Fave G., Oberg K., Interferon-α and Somatostatin Analog in Patients with Gastroenteropancreatic Neuroendocrine Carcinoma: Single Agent or Combination?, Ann. Oncol, 18, pp. 13-19, (2007)
[10] Bosman F.T., Carneiro F., Hruban R.H., Theise N.D., WHO Classification of Tumours of the Digestive System, 3, (2010)

← 1 2 3 4 →